

**UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF CALIFORNIA**

KURT ZIEGLER and DANIEL BRADY,
Individually and on Behalf of All Others Similarly
Situated,

Plaintiff,

v.

GW PHARMACEUTICALS, PLC, JUSTIN
GOVER, GEOFFREY GUY, CABOT BROWN,
DAVID GRYSKA, CATHERINE MACKEY,
JAMES NOBLE, ALICIA SECOR, and LORD
WILLIAM WALDEGRAVE,

Defendants.

CASE NO. 3:21-CV-01019-BAS-MSB

SUMMARY NOTICE

EXHIBIT A-3

TO: ALL RECORD HOLDERS AND ALL BENEFICIAL HOLDERS OF GW PHARMACEUTICALS, PLC (“GW”) AMERICAN DEPOSITARY SHARES (“ADSs”) WHO PURCHASED, SOLD, OR HELD SUCH ADSs AT ANY TIME DURING THE PERIOD FROM AND INCLUDING MARCH 10, 2021, THE RECORD DATE FOR VOTING ON JAZZ PHARMACEUTICALS, PLC’S ACQUISITION OF GW (THE “ACQUISITION” OR “MERGER”), THROUGH AND INCLUDING MAY 5, 2021, THE DATE THE ACQUISITION CLOSED, INCLUDING ANY AND ALL OF THEIR RESPECTIVE PREDECESSORS, SUCCESSORS, TRUSTEES, EXECUTORS, ADMINISTRATORS, ESTATES, LEGAL REPRESENTATIVES, HEIRS, ASSIGNS AND TRANSFEREES (THE “SETTLEMENT CLASS”).

YOU ARE HEREBY NOTIFIED, pursuant to an Order of the United States District Court for the District of Southern California, that a hearing will be held on _____, 2023, at ___:___ .m., before the Honorable Cynthia A. Bashant at the United States District Court for the Southern District of California, James M. Carter and Judith N. Keep United States Courthouse, 333 West Broadway, San Diego, CA 92101. Settlement Class Members should check the Settlement Class website in advance of the Final Approval Hearing to determine whether that hearing instead will occur via a remote link. The hearing will be held for the purpose of determining: (1) whether the proposed Settlement of the Litigation for \$7.75 million should be approved by the Court as fair, reasonable, and adequate; (2) whether a Final Judgment and Order of Dismissal with Prejudice should be entered by the Court dismissing the Litigation with prejudice and releasing the Released Claims against Defendants and Defendants’ Released Persons; (3) whether final certification of the Settlement Class, Lead Plaintiffs, and Lead Counsel should be granted; (4) whether the Plan of Allocation for the Net Settlement Fund is fair, reasonable, and adequate and should be approved; and (5) whether the application of Lead Counsel for the payment of attorneys’ fees and expenses, and any award to Lead Plaintiffs pursuant to 15 U.S.C. §78u-4(a)(4) should be approved.

IF YOU PURCHASED, SOLD OR HELD GW ADSs AT ANY TIME DURING THE PERIOD FROM AND INCLUDING MARCH 10, 2021 THROUGH AND INCLUDING MAY 5, 2021 (THE “SETTLEMENT CLASS PERIOD”), YOUR RIGHTS MAY BE AFFECTED BY THE SETTLEMENT OF THIS LITIGATION, INCLUDING THE RELEASE AND EXTINGUISHMENT OF CLAIMS YOU MAY POSSESS RELATING TO YOUR PURCHASE OR ACQUISITION OF GW ADSs DURING THE SETTLEMENT CLASS PERIOD. If you have not received a detailed Notice of Pendency and Proposed Settlement of Class Action (“Notice”) and a copy of the Proof of Claim and Release form, you may obtain copies by writing to ZIEGLER V GW PHARMACEUTICALS C/O RUST CONSULTING, INC., CLAIMS ADMINISTRATOR – 7961, PO Box 2599, Faribault, MN 55021-9599, (833) 472-1978, or on the Internet at www.gwsecuritieslitigation.com. If you are a Settlement Class Member, in order to share in the distribution of the Net Settlement Fund, you must submit a Proof of Claim and Release by mail (*postmarked no later than* [REDACTED], 2023), or online at www.gwsecuritieslitigation.com, *no later than* [REDACTED], 2023, establishing that you are entitled to recovery.

If you purchased, sold, or held GW ADSs at any time during the Settlement Class Period and you desire to be excluded from the Settlement Class, you must submit a request for exclusion so that it is *received no later than* [REDACTED], in the manner and form explained in the detailed Notice referred to above. All Members of the Settlement Class who do not timely and validly request exclusion from the Settlement Class will be bound by any judgment entered in the Litigation pursuant to the Stipulation of Settlement.

Any objection to the Settlement, the Plan of Allocation, Lead Counsel’s request for the payment of attorneys’ fees and expenses, and any award to Lead Plaintiffs must be received by each of the following recipients via hard copy and email *no later than* [REDACTED]:

CLERK OF THE COURT
UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF CALIFORNIA
James M. Carter and Judith N. Keep United States Courthouse
333 West Broadway
San Diego, CA 92101

Lead Counsel:

Juan E. Monteverde
Monteverde & Associates PC
The Empire State Building
350 Fifth Avenue, Suite 4405
New York, New York 10118
jmonteverde@monteverdelaw.com

Michael Palestina
Kahn Swick & Foti, LLC
1100 Poydras Street, Suite 960
New Orleans, LA 70163
michael.palestina@ksfcounsel.com

Counsel for Defendants:

Rachelle Silverberg
Wachtell, Lipton, Rosen & Katz
51 W. 52nd Street
New York, New York 10019
RSilverberg@WLRK.com

PLEASE DO NOT CONTACT THE COURT OR THE CLERK'S OFFICE REGARDING

THIS NOTICE. If you have any questions about the Settlement, you may contact Lead Counsel at the address listed above.

Dated: _____

BY ORDER OF THE COURT
UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF CALIFORNIA